Search Results
Search for other papers by Emmanouil Saloustros in
Google Scholar
PubMed
Search for other papers by Paraskevi Salpea in
Google Scholar
PubMed
Search for other papers by Matthew Starost in
Google Scholar
PubMed
Search for other papers by Sissi Liu in
Google Scholar
PubMed
Search for other papers by Fabio R Faucz in
Google Scholar
PubMed
Search for other papers by Edra London in
Google Scholar
PubMed
Search for other papers by Eva Szarek in
Google Scholar
PubMed
Search for other papers by Woo-Jin Song in
Google Scholar
PubMed
Search for other papers by Mehboob Hussain in
Google Scholar
PubMed
Search for other papers by Constantine A Stratakis in
Google Scholar
PubMed
(5%) also formed in the aged heterozygote ( Prkar1a +/− ) mouse. To better understand the role of PRKAR1A in the pancreas, we knocked out Prkar1a in pdx1 -expressing cells. Interestingly, these mice developed with high-penetrance malignant
Search for other papers by Roberto Valente in
Google Scholar
PubMed
Search for other papers by Alastair J Hayes in
Google Scholar
PubMed
Search for other papers by Sven-Petter Haugvik in
Google Scholar
PubMed
Search for other papers by Per Hedenström in
Google Scholar
PubMed
Search for other papers by Darko Siuka in
Google Scholar
PubMed
Search for other papers by Emilie Korsæth in
Google Scholar
PubMed
Search for other papers by Daniel Kämmerer in
Google Scholar
PubMed
Search for other papers by Stuart M Robinson in
Google Scholar
PubMed
Search for other papers by Patrick Maisonneuve in
Google Scholar
PubMed
Search for other papers by Gianfranco Delle Fave in
Google Scholar
PubMed
Search for other papers by Bjorn Lindkvist in
Google Scholar
PubMed
Search for other papers by Gabriele Capurso in
Google Scholar
PubMed
Introduction Pancreatic neuroendocrine neoplasms (PNENs) are a group of tumors which originate from endocrine cells within the pancreas gland. PNENs have heterogeneous clinical behavior owing to their hormone functional status, cellular
Search for other papers by Margaux Foulfoin in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, Lyon, France
Search for other papers by Emmanuelle Graillot in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de chirurgie, Lyon, France
Search for other papers by Mustapha Adham in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service de radiologie, Lyon, France
Search for other papers by Pascal Rousset in
Google Scholar
PubMed
Search for other papers by Julien Forestier in
Google Scholar
PubMed
Hospices Civils de Lyon, Hôpital Edouard Herriot, Service Central d’Anatomie et Cytologie Pathologiques, Lyon, France
Search for other papers by Valérie Hervieu in
Google Scholar
PubMed
Search for other papers by Philip Robinson in
Google Scholar
PubMed
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
University of Lyon, Université Lyon 1, Lyon, France
Search for other papers by Thomas Walter in
Google Scholar
PubMed
the first occurrence of metastases for metachronous disease: gender, age, ECOG performance status (PS), primary tumor location (head, body or tail of the pancreas), functional status, serum plasma levels of chromogranin A (CgA), serum alkaline
Search for other papers by Kimberly Kamp in
Google Scholar
PubMed
Search for other papers by Ronald A M Damhuis in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
gastrointestinal (GE) and bronchopulmonary tracts, and pancreas. In addition, these tumors can also be found in other more rare primary localizations such as ovaries, liver, and kidneys. NETs that originate from cells of the diffuse neuroendocrine system of the
Search for other papers by Nele Garbrecht in
Google Scholar
PubMed
Search for other papers by Martin Anlauf in
Google Scholar
PubMed
Search for other papers by Anja Schmitt in
Google Scholar
PubMed
Search for other papers by Tobias Henopp in
Google Scholar
PubMed
Search for other papers by Bence Sipos in
Google Scholar
PubMed
Search for other papers by Andreas Raffel in
Google Scholar
PubMed
Search for other papers by Claus F Eisenberger in
Google Scholar
PubMed
Search for other papers by Wolfram T Knoefel in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Christian Fottner in
Google Scholar
PubMed
Search for other papers by Thomas J Musholt in
Google Scholar
PubMed
Search for other papers by Anja Rinke in
Google Scholar
PubMed
Search for other papers by Rudolf Arnold in
Google Scholar
PubMed
Search for other papers by Uta Berndt in
Google Scholar
PubMed
Search for other papers by Ursula Plöckinger in
Google Scholar
PubMed
Search for other papers by Bertram Wiedenmann in
Google Scholar
PubMed
Search for other papers by Holger Moch in
Google Scholar
PubMed
Search for other papers by Philipp U Heitz in
Google Scholar
PubMed
Department of Pathology, Department of Pathology, Department of General, Department of Gastroenterology and Endocrinology, Department of Endocrinology, Department of General and Abdominal Surgery, Department of Gastroenterology and Endocrinology, Department of Hepatology and Gastroenterology, Department of Pathology, Institute of Pathology, University of Kiel, Michaelisstr. 11, 24105 Kiel, Germany
Search for other papers by Paul Komminoth in
Google Scholar
PubMed
Department of Pathology, Department of Pathology, Department of General, Department of Gastroenterology and Endocrinology, Department of Endocrinology, Department of General and Abdominal Surgery, Department of Gastroenterology and Endocrinology, Department of Hepatology and Gastroenterology, Department of Pathology, Institute of Pathology, University of Kiel, Michaelisstr. 11, 24105 Kiel, Germany
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Introduction Neuroendocrine tumors (NETs) of the stomach, intestine, and pancreas are heterogeneous, as far as their morphology, function, and biology are concerned. The WHO classification therefore distinguishes the gastroenteropancreatic NETs
Université de Paris, Centre de Recherche sur l’Inflammation, INSERM, Paris, France
Search for other papers by Ophélie De Rycke in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
Search for other papers by Marine Perrier in
Google Scholar
PubMed
Search for other papers by Olivia Hentic in
Google Scholar
PubMed
Search for other papers by Catherine Lombard-Bohas in
Google Scholar
PubMed
Search for other papers by Romain Coriat in
Google Scholar
PubMed
Search for other papers by Guillaume Cadiot in
Google Scholar
PubMed
Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital, Paris/Clichy, France
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Université de Paris, Centre de Recherche sur l’Inflammation, INSERM, Paris, France
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
Department of Pathology, ENETS Centre of Excellence, Bichat/Beaujon University Hospital, Paris/Clichy, France
Search for other papers by Jérôme Cros in
Google Scholar
PubMed
Université de Paris, Centre de Recherche sur l’Inflammation, INSERM, Paris, France
Search for other papers by Louis de Mestier in
Google Scholar
PubMed
Raj N Reidy-Lagunes D 2020 Exceptional responses after cessation of therapy With alkylating agents for pancreatic neuroendocrine tumors . Pancreas 49 e14 – e16 . ( https://doi.org/10.1097/MPA.0000000000001451 ) Zehir A Benayed R Shah
Search for other papers by W W de Herder in
Google Scholar
PubMed
Search for other papers by E P Krenning in
Google Scholar
PubMed
Search for other papers by C H J Van Eijck in
Google Scholar
PubMed
Search for other papers by S W J Lamberts in
Google Scholar
PubMed
Endocrine tumours of the gastrointestinal tract and pancreas may present at different disease stages with either hormonal or hormone-related symptoms/syndromes, or without hormonal symptoms. They may occur either sporadically or as part of hereditary syndromes. In the therapeutic approach to a patient with these tumours, excessive hormonal secretion and/or its effects should always be controlled first. Tumour-related deficiencies or disorders should also be corrected. Subsequently, control should be aimed at the tumour growth. Surgery is generally considered as first-line therapy for patients with localized disease, as it can be curative. However, in patients with metastatic disease the role of first-line surgery is not clearly established and other therapies should be considered, such as non-surgical cytoreductive therapies, biotherapy (with somatostatin analogues or interferon-alpha), embolization and chemoembolization of liver metastases, chemotherapy (with single or multiple dose regimens) and peptide receptor-targeted radiotherapy. The delicate balance of the use of the different therapeutical options in patients with endocrine tumours of the gastrointestinal tract and pancreas emphasizes the importance of team approach and team expertise.
Member of the German Cancer Consortium (DKTK), Germany
Search for other papers by Atsuko Kasajima in
Google Scholar
PubMed
Search for other papers by Günter Klöppel in
Google Scholar
PubMed
, intestinum and lung, since it was coined by Oberndorfer in 1907 in his seminal work on the NETs of the ileum, and defined by Hamperl in 1937 for the NETs of the lung ( Hamperl 1937 ). Islet cell tumor is the term that denotes the NETs of the pancreas because
Search for other papers by Taymeyah Al-Toubah in
Google Scholar
PubMed
Università, Vita e Salute, Milan, Italy
Search for other papers by Stefano Partelli in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Valentina Andreasi in
Google Scholar
PubMed
Search for other papers by Franco Silvestris in
Google Scholar
PubMed
Università, Vita e Salute, Milan, Italy
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Daniel A Anaya in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Introduction Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a heterogeneous group of tumors which include NETs of the gastrointestinal tract and pancreas. Tumor grade and differentiation are important prognostic factors. Low
Search for other papers by G Rindi in
Google Scholar
PubMed
Search for other papers by C Bordi in
Google Scholar
PubMed
Originating from cells of the diffuse endocrine system the endocrine tumours of the gut and the pancreatic tract are rare entities characterized by a common phenotypic aspect and producing several bioactive substances including growth factors. Two major categories are identified: well-differentiated and poorly differentiated tumours. The clinical behaviour varies ranging from benign to low grade malignant for well-differentiated tumours/carcinomas to high grade malignant for poorly differentiated carcinomas. The two major categories of well-differentiated and poorly differentiated tumours display distinct phenotypes and genetic backgrounds possibly supporting distinct histogenesis. Genetic abnormalities associated with either induction or progression of tumours may vary depending on the site of origin.